{"id":"menatetranone-mk4","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Generally well-tolerated"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"MK4 functions as a cofactor for gamma-carboxylation of osteocalcin and matrix Gla protein, which are critical for bone formation and prevention of vascular calcification. By enhancing the carboxylation of these vitamin K-dependent proteins, MK4 promotes bone mineral density and may reduce fracture risk while preventing pathological calcification in soft tissues.","oneSentence":"Menatetrenone (MK4) is a form of vitamin K2 that activates vitamin K-dependent proteins involved in bone mineralization and vascular calcification regulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:41.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis prevention and treatment"},{"name":"Bone mineral density improvement in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT00062595","phase":"PHASE3","title":"Vitamin K and Bone Turnover in Postmenopausal Women","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2000-09","conditions":"Osteoporosis","enrollment":375}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":145,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"menatetranone (MK4)","genericName":"menatetranone (MK4)","companyName":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","companyId":"national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Menatetranone (MK4) is a small molecule that has been studied in clinical trials for its potential effects on osteoporosis. It was compared to phylloquinone (K1) in a 2005 study on bone turnover in postmenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}